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Abstract
Introduction
Genome-Wide Association Studies have identified associations between lung function
measures and Chronic Obstructive Pulmonary Disease (COPD) and chromosome region
6p21 containing the gene for the Advanced Glycation End Product Receptor (AGER,
encoding RAGE). We aimed to (i) characterise RAGE expression in the lung, (ii) identify
AGER transcripts, (iii) ascertain if SNP rs2070600 (Gly82Ser C/T) is associated with lung
function and serum sRAGE levels and (iv) identify whether the Gly82Ser variant is function-
ally important in altering sRAGE levels in an airway epithelial cell model.
Methods
Immunohistochemistry was used to identify RAGE protein expression in 26 human tissues
and qPCR was used to quantify AGER mRNA in lung cells. Gene expression array data
was used to identify AGER expression during lung development in 38 fetal lung samples.
RNA-Seq was used to identify AGER transcripts in lung cells. sRAGE levels were assessed
in cells and patient serum by ELISA. BEAS2B-R1 cells were transfected to overexpress
RAGE protein with either the Gly82 or Ser82 variant and sRAGE levels identified.
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Results
Immunohistochemical assessment of 6 adult lung samples identified high RAGE expres-
sion in the alveoli of healthy adults and individuals with COPD. AGER/RAGE expression
increased across developmental stages in human fetal lung at both the mRNA (38 sam-
ples) and protein levels (20 samples). Extensive AGER splicing was identified. The
rs2070600T (Ser82) allele is associated with higher FEV1, FEV1/FVC and lower serum
sRAGE levels in UK smokers. Using an airway epithelium model overexpressing the Gly82
or Ser82 variants we found that HMGB1 activation of the RAGE-Ser82 receptor results in
lower sRAGE production.
Conclusions
This study provides new information regarding the expression profile and potential role of
RAGE in the human lung and shows a functional role of the Gly82Ser variant. These find-
ings advance our understanding of the potential mechanisms underlying COPD particularly
for carriers of this AGER polymorphism.
Introduction
Lung diseases including chronic obstructive pulmonary disease (COPD) remain a major bur-
den to society and the economy. In recent years there has been substantial progress in our
understanding of genetic factors associated with lung function parameters through genome
wide association approaches [1–4]. There is a key need however, to define the mechanisms
which underlie the identified associations.Meta-analyses of genome-wide association studies
(GWAS) have identified polymorphisms in the Advanced Glycation End Product-Specific
gene (AGER, pivotal SNP in exon 3 rs2070600 (Gly82Ser, C/T)) as being associated with
Forced Expiratory Volume in 1 second (FEV1)/Forced Vital capacity (FVC) [1, 2]. The role of
AGER now requires further elucidation in the lung which may provide new insight into the
mechanisms underlying several lung diseases whereAGER genetic variants have been impli-
cated, including e.g. COPD and lung cancer [5, 6]. AGER encodes RAGE; a member of the
immunoglobulin superfamily which interacts with a diverse range of ligands, including damage
associatedmolecular pattern proteins such as High mobility group protein B1 (HMGB1). Acti-
vation of RAGE has many downstream effects including the regulation of inflammation, cell
migration, proliferation and adhesion [7, 8]. Importantly, accumulating data suggests RAGE
may play a role in a range of diseases including COPD [5, 9, 10], Alzheimer’s disease, arthritis
and diabetes [11–13] and so a greater understanding of AGER regulation by genetic mecha-
nisms has broad implications. RAGE is expressed abundantly in the membrane and cytoplasm
of both pneumocytes and macrophages in lung [14], suggesting an important role in lung
homeostasis. Recent studies in transgenic mouse models have shown a role for RAGE in alveo-
lar morphogenesis during lung development [15] with overexpression of RAGE also being
shown to result in the development of an emphysema-like phenotype in adult mice [16].
Increased expression of RAGE, or the soluble forms of the receptor generated by cleavage
(sRAGE) or mRNA splicing (esRAGE), has been found in the airways and serum of COPD
patients [5, 9, 10]. However, the mechanism underlying the genetic association with lung func-
tion seen at this locus has as yet not been defined. In the current study we set out specifically to
further define the potential role of AGER in the context of respiratory disease. To do this we
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have determined the expression profile of RAGE in human lung and during lung development.
Additionally, we have investigated the specific functional effects of the key Gly82Ser variant
that has been associated with numerous lung phenotypes at both the population and cellular
levels providing an insight into the function of this variant in the lung.
Methods
Immunohistochemistry
Three control (no history of obstructive lung disease) adult lung samples and three samples
from individuals with clinically diagnosedCOPD were provided by the Nottingham Health
Science Biobank following isolation by lung resection (Nottingham, UK) under ethical
approval (08/H0407/1). Twenty fetal lung tissue samples were provided by The Human Devel-
opmental Biology Resource (www.hdbr.org) at different stages, specifically 19, 21 and 23 days
and 9, 10, 11, 12, 13, 14, 15, 16, 17 and 19 weeks post-conception. Immunohistochemistry was
performed as previously described [17]. Slides were incubated with either a rabbit polyclonal
anti-RAGE antibody (1:500, ab30381, Abcam, Cambridge, UK) or normal rabbit IgG isotype
control (Invitrogen/Life Technologies Ltd.) for 1 hour at room temperature.
Affymetrix U133 Plus 2 array data for human fetal lung
Prior studies have obtained human fetal lung tissues from the National Institute of Child
Health and Human Development tissue databases and the extracted RNA profiled using
microarrays to investigate gene expression spanning different gestational ages [18, 19]. RNA
samples from 38 subjects (estimated gestational age 7–22 weeks or 53–154 days post concep-
tion) i.e. Pseudoglandular (gestational age, 7–16 weeks) and into the Canalicular (17–26
weeks) stages of development were used in the currentAGER analyses. These data are available
at NCBI Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo),GSE14334.
Affymetrix probes; 217046_s_at and 210081_at were used for AGER expression analyses in
relation to gestational age (linear regression model (lmFit) as implemented in the Limma pack-
age in R/Bioconductor).
Quantitative PCR
Quantification of total AGERmRNA was carried out using total RNA from cultured cells or
commercially available total lung tissue (Ambion/Life Technologies) using Taqman™ (Applied
Biosystems/Life Technologies) as previously described [20]. In each sample, quantitative PCR
(qPCR) was carried out for AGER (Assay VY4331182 designed to detect part of the 5’region
and thus detects the majority of transcripts, Invitrogen) and Human 18S ribosomal RNA 1
endogenous control (4310893E, Applied Biosystems). qPCR was performed using a Stratagene
Mx3005P machine (Agilent Technologies, UK). Data were analysed using the 2-ΔΔCt method.
RNA Sequencing
Total RNA was extracted from normal human bronchial epithelial cells (NHBECs) from three
donors (Lonza, UK) at either passage 3 or 4 using the GenEluteMammalian Total RNA Mini-
prep Kit (Sigma-Aldrich).Donor 1 was a Caucasian, 56 years old, Male, Smoker; Donor 2 was
a 19 year old, Male, Smoker and Donor 3 was a Caucasian, 50 year old, Male, Smoker. RNA
quality was assessed using the Agilent 2100 Bioanalyzer with all samples having a RNA integ-
rity number 8. A sequencing library was prepared using TruSeq RNA Sample Prep Kit v2
(Illumina). mRNA was poly-A selected using oligo-dT coated magnetic beads and fragmented.
cDNA was synthesised using random primers. Finally, a cDNA library was prepared by end-
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repair, phosphorylation, A-tailing, adapter ligation and PCR amplification. Paired-end
sequencingwas performed on either the Illumina HiSeq 2000 or the NextSeq 500 with approxi-
mately 40 million reads per sample generated. RNA-seq data was analysed as described [21].
The raw read FastQ files (100 base pair reads) were quality evaluated using FastQC.Median
quality scores were above 28 for all samples. Reads were used for subsequent analysis using the
Ubuntu 12.04 LTS operating system. Reads were aligned to the human genome (Build
GRCh37) for each sample using Bowtie2 tool as part of TopHat (v2.0.12). Reads aligning to
more than 20 positions were discarded. The Cufflinks v2.2.1 programme was used to assemble
transcriptomes for each individual sample. Transcriptomes from all the samples were merged
by reference annotation based transcript assembly (RABTA) using Cuffmerge v1.0.0 to provide
the maximum reads to identify low-expression transcripts. The Cuffmerge generated novel
gene transfer format (GTF) annotation file was compared to the Ensembl GTF annotation of
the GRCh37 genome build using Cuffcompare v2.2.1. Basal NHBEC sample data (n = 3) were
used to identify transcript abundance. Mean fragments per kilobase of transcript per million
fragments mapped (FPKM) expression of isoforms was calculated and percent of total tran-
scripts determined. Splicing graphs were generated using SpliceGrapher v0.2.4.
Patient recruitment, genotyping and ELISA
Subjects were recruited from five UK centres for smoking history and/or COPD diagnosis, this
cohort is the same as that previously described [22, 23]. This generated a cohort for lung func-
tion association analyses composed of 1042 smokers with DNA samples available. rs2070600
was genotyped using the LGC Genomics KBioscience service (Herts, UK). We generated a sub-
group based on rs2070600 genotype composed of 102 subjects for serum analyses (51 C:T and
51 C:C age, sex and smoking pack year matched). The level of sRAGE in the serumwas deter-
mined using the Quantikine ELISA kit for Human RAGE as directed by the manufacturer (R &
D systems, UK). Ethical approval was obtained from local ethics committees (Nottingham,
Sheffield,Manchester, Leicester and Oxford).
Site-directed mutagenesis and transfection of BEAS2B-R1 cells
A plasmid containing the cDNA for the full length, membrane form of RAGE (pcDNA3.1-fl-
RAGE) was a kind gift of Dr. B. Hudson (University of Miami). Site directedmutagenesis of
the flRAGE plasmid was carried out using QuikChange1 Multi Site-directedMutagenesis kit
(Agilent, UK). A single mutagenic primer (CGTGTCCTTCCCAAC(A)GCTCCCTCTTCCT)was
used to generate the alternative allele of SNP rs2070600. All constructs were sequence verified
(data not shown). BEAS2B-R1 epithelial cells (provided by Dr. Ray Penn, University of Mary-
land, Baltimore, USA) [24] were transiently transfected with plasmids using Fugene 6 (Pro-
mega, UK) at a 3:2 Fugene:DNA ratio, grown for 24 hours and then serum starved for 16
hours. 250ng/ml of HMGB1 ligand (R & D systems, UK, 1690-HMB-025) was then added to
the cells for 48 hours. Supernatants were collected for analysis and sRAGE levels measured as
described for serum analyses. Cells were lysed and RNA extracted using the GenEluteMamma-
lian Total RNA miniprep kit (Sigma). cDNA was synthesised using the Superscript First-Strand
Synthesis System for RT-PCR (Invitrogen/Life Technologies). qPCR for AGER was performed
as described.Data from four independent cell experiments were combined for analyses.
Statistical analysis
Linear regression was used to assess association between lung functionmeasures (FEV1, FVC
and FEV1/FVC) and rs2070600 genotype or log serum sRAGE levels as previously described
[2]. Mann-Whitney tests were used to compare groups (GraphPad Prism 6).
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Results
RAGE expression and localisation in healthy and COPD lungs
The expression of RAGE (encoded by AGER) was determined in the alveoli and bronchi of
control and COPD lungs using immunohistochemistry. Specific staining was observed in both
the cytoplasm and membrane (Fig 1). Pneumocytes within the alveolar regions of all three lung
samples from control individuals exhibited strong staining for RAGE (Fig 1a) and in these
samples the bronchial epithelium showed a variable, weaker staining pattern for RAGE
(Fig 1e). In the lung tissue of all three individuals with COPD, strong immuno-positivity for
Fig 1. Immunohistochemical analysis of RAGE expression in healthy and COPD lung. In healthy lung
tissue, RAGE was found to be localised to the cytoplasm and membrane. RAGE expression was high in the
pneumocytes of alveolar regions (a). The bronchial epithelium showed variable weak to moderate staining
(e). In lung tissue of individuals with COPD, RAGE was very strongly immunopositive in the membrane and
cytoplasm of the pneumocytes in the alveolar regions (b). The bronchial epithelium from individuals with
COPD was weak or immunonegative for the RAGE protein (f). All isotype controls were negative (c, d, g and
h). Representative images of one healthy and one COPD lung shown. x10 magnification.
doi:10.1371/journal.pone.0164041.g001
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RAGE was found both in the membrane and cytoplasm of pneumoctyes in the alveolar regions
(Fig 1b), whilst the bronchial epithelium showed limited RAGE expression (Fig 1f).
AGER mRNA and RAGE protein expression increase during lung
development
The abundance of AGERmRNA in thirty eight human fetal lung samples was assessed using
publically available expression microarray data (see methods). Levels of AGERmRNA were
found to increase with gestational age across the Pseudoglandular and into the Canalicular
stages of human lung development (gestational ages, 7–16 weeks and 17–26 weeks, respec-
tively), (Fig 2 and Table 1).
38 human lung tissue samples from gestational ages 7–22 weeks (or 53–154 days post con-
ception) were assessed. AveExpr = average expression between all samples, t = t-statistic
describing differential expression, P value = unadjusted P value, Adj.P.value = adjusted P value
controlling for false discovery rate, Beta-coefficient= log (odds ratio) corresponding to the
Fig 2. Gene expression array data of 38 fetal lungs for the AGER probes. Expression intensities for the AGER
probes 210081_at and 217046_s_at were plotted against the gestational age of each fetal lung sample and showed an
increase in expression with fetal lung age. RMA; Robust Multi-array Average. Affymetrix U133 Plus 2 expression array
probe 210081_at probes for exon 8 of AGER mRNA whilst 217046_s_at probes AGER exons 7–11’.
doi:10.1371/journal.pone.0164041.g002
Table 1. Fetal lung gene array data for AGER expression across Pseudoglandular and Canalicular stages.
Probe ID AveExpr t P value Adj P value Beta-coeffient
217046_s_at 5.6868 2.985 0.0051 0.0251 0.0066
210081_at 6.3418 5.0807 9.51E-06 0.0002 0.0151
doi:10.1371/journal.pone.0164041.t001
Characterisation of AGER/RAGE in the Human Lung
PLOS ONE | DOI:10.1371/journal.pone.0164041 October 18, 2016 6 / 16
mean change in gene expression per day during the gestational age period studied, 7–22 weeks
of gestational age (data analysed as described [18]).
Having observed increasing levels of AGERmRNA through fetal development, levels of
RAGE protein during lung development were assessed via immunohistochemistry. RAGE
expression was also observed to increase during lung development across the 20 fetal lung sam-
ples; from absent to low expression in the early embryonic stages to increasing RAGE expression
in the developing bronchi/bronchioles of the later embryonic stages (Fig 3a–3f). RAGE expres-
sion continued to increase across the Pseudoglandular and Canalicular stages (Fig 3g–3t).
AGER mRNA levels and splice variation in airway structural cells
A total AGER quantitative PCR (qPCR) assay was used to determine the expression of AGER
mRNA in human lung and in airway cell populations, specifically bronchial epithelium and air-
way smooth muscle cells.AGER was highly expressed in total lung whereas cultured human
airway smoothmuscle, NHBEC and BEAS2B-R1 cells exhibited lower levels of AGERmRNA
(Fig 4). Having assessed the relative abundance of AGER transcripts between these cell types,
we then assessed which isoforms were expressed. A large number of differentially spliced
AGER transcripts have been previously described in lung tissue [25]. To identifyAGER tran-
scripts in structural cells of the airways, RNA Sequencing (RNA Seq) was used to defineAGER
splicing and isoform abundance in cultured primary human bronchial epithelial cells from
three independent donors (Fig 5). Using this approach we confirmed the presence and abun-
dance of several knownAGER transcripts in human bronchial epithelial cells, however there
was heterogeneity in expression across the donors. Interestingly, several novel variants contain-
ing exons belonging to the neighbouring gene PCL2, spliced together with previously annotated
AGER exons were identified.However, while spliced transcripts were seen in all three donors,
there was inconsistency in the site of splicing and abundancy of novel variants and it remains
unclear whether or not these transcripts are translated (data not shown).
Fig 3. Immunohistochemical analysis of RAGE’s expression in fetal lung. Fetal lung tissue samples from embryonic (3–7 weeks), pseudoglandular
(7–15 weeks) and canalicular (16–26 weeks) stages of development showed an increase in RAGE protein expression with increasing fetal lung age. a-t
represent age ordered lung samples of 19 days (a, b), 21 days (c, d), 23 days (e, f), 9 weeks (g), 10 weeks (h,i,j), 11 weeks (k), 12 weeks (l,m,n), 13
weeks (o), 14 weeks (p), 15 weeks (q), 16 weeks (r), 17 weeks (s) and 19 weeks (t). All isotype controls were negative (data not shown). x40
magnification.
doi:10.1371/journal.pone.0164041.g003
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Fig 4. AGER mRNA expression levels in total lung and airway cells. Q-PCR analysis identified AGER
mRNA was highly expressed in total lung and at lower levels in human airway smooth muscle cells (HASM)
cells, human bronchial epithelial cells (HBEC) and the BEAS-2BR1 bronchial epithelial cell line, (n = 3).
doi:10.1371/journal.pone.0164041.g004
Fig 5. AGER isoform expression in three HBEC donors using RNA Seq. Structure and abundance of
known AGER isoforms in three human bronchial epithelial cell donors illustrating heterogeneity in expression
levels. Percentage abundances (% FPKM) were calculated for each donor. Transcripts for full length and
soluble AGER were identified at similar low abundancies. FPKM; fragments per kilobase of transcript per
million mapped reads.
doi:10.1371/journal.pone.0164041.g005
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rs2070600 is associated with lung function and sRAGE levels in the
serum of a cohort of UK smokers
We analysed 1042 DNA samples from individuals who currently smoke and have a history of
smoking recruited from five UK centres to assess the association of sRAGE levels with lung
function by genotype. The minor allele frequency in this population for the Ser82 variant was
10%. Serum samples were analysed from 102 of these subjects who were either homozygous for
the Gly82 variant or heterozygous i.e. Gly82/Ser82. Baseline characteristics of the subjects stud-
ied are shown in Table 2.
We identified association between rs2070600T and increased FEV1 and FEV1/FVC ratio
(P = 0.031 and P = 0.028, respectively), (S1 Table). Serum from 102 subjects in the genotyping
cohort was selected based on rs2070600 genotype; providing 51 heterozygotes (C/T) and 51
homozygotes (C/C) for comparison (T/T subjects not available). These groups were matched
for age, sex and smoking pack years (Table 2). Serum sRAGE levels were significantly lower in
individuals with the Ser82 genotype compared to individuals homozygous for Gly82
(P< 0.0001) showing that that the Ser82 variant leads to reduced sRAGE levels in vivo (Fig 6(i)
and S2 Table). We did not identify a significant association between serum sRAGE levels and
FEV1, FVC or FEV1/FVC when subjects were stratified by genotype potentially due to low num-
bers of subjects (S3 Table).
Table 2. Baseline characteristics of UK smoker population used for genetic association studies.
rs2070600 genotyping
(n = 1042)
Subgroup used for serum sRAGE
(Gly82Gly) (n = 51)
Subgroup used for serum sRAGE
(Gly82Ser) (n = 51)
Age in years (mean ± SD) 70.0 ± 10.3 (n = 1042) 68.2 ± 7.6 (n = 51) 68.1 ± 7.9 (n = 51)
Female % (n) 43 (n = 1042) 31 (16 of 51) 31 (16 of 51)
FEV1 in litres (mean ± SD) 1.50 ± 0.87 (n = 1036) 1.26 ± 0.66 (n = 50) 1.30 ± 0.72 (n = 51)
FEV1 percent predicted
(mean ± SD)
53.34 ± 25.47 (n = 1013) 48.00 ± 17.79 (n = 50) 48.68 ± 22.34 (n = 51)
FEV1/FVC as % (mean ± SD) 55 ± 17 (n = 1028) 45 ± 12 (n = 49) 48 ± 14 (n = 50)
Pack years (mean ± SD) 45 ± 28 (n = 1017) 52 ± 30 (n = 50) 52 ± 31 (n = 49)
doi:10.1371/journal.pone.0164041.t002
Fig 6. The genotype effect of rs2070600. Serum sRAGE levels are lower in individuals with the C:T genotype at rs2070600
(p<0.0001, Mann-Whitney) (6i). Cells expressing RAGE-Ser82 (T allele) stimulated with HMGB1 for 48 hours had lower
levels of sRAGE than RAGE-Gly82 (C allele) carrying cells (n = 4, p = 0.036), (6ii).
doi:10.1371/journal.pone.0164041.g006
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Activation of RAGE-Ser82 leads to lower sRAGE levels compared to
RAGE-Gly82 in an epithelial cell model
To investigate the functional significance of SNP rs2070600 in the context of the full length
membrane bound receptor, we created a recombinant RAGE epithelial cell model, with cells
engineered to express the full length RAGE coding region with either the T allele (Ser82) or
the C allele (Gly82) of rs2070600. Transient transfection of allele-specificRAGE plasmids
into BEAS2B-R1 (bronchial epithelial) cells resulted in a significant induction of AGER
mRNA (mean 2500 fold change at the mRNA level) suggesting confounding from the very
low endogenous expression of RAGE is unlikely to influence our findings. Stimulation with
or without HMGB1 resulted in differing levels of sRAGE secretion in a genotype specific
manner (Fig 6(ii)). Cells transfected with the AGER-Ser82 plasmid produced lower levels of
sRAGE in the presence of HMGB1 compared to RAGE-Gly82 transfected cells, P = 0.036
(Fig 6(ii)). We did not identify a significant difference in the levels of total AGERmRNA in
RAGE-Ser82 versus RAGE-Gly82 expressing cells (data not shown) suggesting that the effect
of the T allele of rs2070600 is not due to altered transcriptional activity.
Discussion
A number of polymorphisms within the AGER locus on chromosome 6p21 have shown repro-
ducible associationwith the lung functionmeasures FEV1 and FEV1/FVC [1,2] and importantly
COPD [5, 26]. The sentinel SNP at this locus is rs2070600, and the T allele at this SNP alters the
amino acid sequence of RAGE from a Glycine at position 82 to a Serine,making this the most
obvious candidate driving functional effects at this locus. In the current study we determined
the expression profile of RAGE in healthy, diseased and the developing human lung demon-
strating high protein expression in the alveoli of healthy adults and individuals with COPD.
Importantly, we have shown for the first time that AGER/RAGE expression increases across
developmental stages in human lung, both at the level of mRNA and protein, with high expres-
sion maintained in adulthood.We characterisedAGER gene structure and transcript abundance
in bronchial epithelial cells revealingmany isoforms confirming the complexity of splice varia-
tion for AGER however we can not exclude that additional variation exists as we only investi-
gated samples from three donors. Splice variants for AGER have previously been identified, with
at least 10 coding for protein, however, only some are validated [25]. We confirmed that the
rs2070600T allele (Ser82) is associated with higher values of FEV1 and FEV1/FVC ratio and pro-
vide new data demonstrating that this allele is associated with lower serum levels of soluble
RAGE in UK smokers in keeping with findings of two previous studies [5, 27]. Levels of sRAGE
have also been associated with a diagnosis of COPD, GOLD classification and severalmeasures
of emphysema using computed tomography (CT) variables [5, 28–30]. Using an allele-specific
RAGE cell model we identified that activation of the RAGE-Ser82 receptor with HMGB1 ligand
leads to secretion of lower levels of soluble RAGE compared to the RAGE-Gly82 receptor dem-
onstrating that rs2070600 is functionally relevant and could underlie the effects on serum
sRAGE observed in vivo. This effect appears to be due to altered cell processing of RAGE, as
there was no obvious effect of the variants on levels of transcription.
Our immunohistochemical data confirm and extend previously published findings that
showed moderate to high expression of RAGE in the alveolar region, with low expression in
the bronchial epithelium [31, 32] and higher expression in lung tissue from patients with
COPD[9, 10]. We observedonly weak staining in bronchial epithelium. This is consistent with
the low levels of mRNA found by qPCR in NHBEC and BEAS2B-R1 cells. RAGE expression
has previously been shown to increase throughout development in neonatal mouse and rat
lung [33, 34]. Therefore our novel finding that RAGE expression increases across human lung
Characterisation of AGER/RAGE in the Human Lung
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developmental stages both complement and extend the experiments in rodents. In keeping
with the evidence presented here that RAGE expression increases with fetal age, Lopez Diez
et al, showed high RAGE expression in 37 week old fetal lung [35]. For the AGERmRNA anal-
yses across fetal stages it is important to note that using two probes to measure gene expression
is a strength and based on the data of Hudson et al. [25] the 210081_at probe (exon 8) would
measure 99% of adult lung transcripts and the 217046s probe (Exon 7–11) would measure 83%
as this region spans alternative splicing forms. This is potentially reflected in the different
intensities for these probes observed (Fig 4). A more recent study also suggested that the major-
ity of AGER transcripts identified in both adult and fetal lung tissue contain exon 8 and so
would be quantified by the 210081_at probe (Lopez-Diez 2013).
A limitation of the fetal immunohistochemistry was the low number of samples at each
developmental stage (especially canalicular). The relationship between increasing RAGE
expression in the fetal lung with increasing age may potentially be explained by cell differentia-
tion and the evolving cellular composition within the developing lung. During the embryonic
stage, early precursor lung cells are present and with increasing differentiation at the pseudo-
glandular stage, alveolar type II pneumocytes are present which express RAGE. Furthermore,
at the canalicular stage of lung development type I pneumocytes are present alongside a larger
differentiated population of type II pneumocytes expressing RAGE.
Importantly, a functional role for RAGE during lung development has recently been dem-
onstrated in mice, with alterations in RAGE levels causing lethality and/or changes to second-
ary septation, hypoplasia, lung tissue loss and changes in pulmonarymicrovasculature [15, 36–
38]. While we cannot evaluate these mechanisms in the human context our differential expres-
sion data in human fetal lung implies a role for AGER in mammalian lung development. Taken
together, these data show that RAGE expression increases through lung development and that
high expression is maintained in the adult lung suggesting a role for RAGE in lung homeosta-
sis. This has implications for the mechanisms underlying the development of COPD as these
finding potentially suggest that individuals with alterations in AGER homeostasis may have
defective lung development and therefore never reach maximal lung function. This is at least in
part supported by the association of AGER SNPs and lung function in children [2]. One limita-
tion of the immunohistochemical study of fetal lung tissue was the availability of only a rela-
tively small number of samples at each developmental stage prohibiting more quantitative or
semi-quantitative analyses. A separate limitation of the study was that we expression profiled
AGERmRNA expression in the BEAS2B-R1 immortalised cell line rather than in lung tissue or
primary cells which would be optimal.
Overall, our data suggest that the Gly82Ser polymorphism alters ligand-dependent release
of sRAGE in the airway. These data compliment and extend previous reports in non-airway
cell systems where it has been shown that Gly82Ser can influence ligand binding and/or recep-
tor activation [12, 39, 40]. RAGE-Ser82 receptors expressed on CHO [12] or COS7 [39] cells
have a lower dissociation constant (Kd) for the RAGE ligand EN-RAGE or glycolaldehyde-
derived AGE respectively compared to RAGE-Gly82 receptors. This reduced Kd for glycolal-
dehyde-derived AGE for RAGE-Ser82 receptors resulted in an enhanced VEGFmRNA induc-
tion demonstrating downstream effects [39]. Subsequently, Park and colleagues demonstrated
that RAGE-Ser82 was consistently glycosylated at Asn81 in vitro whereas RAGE-Gly82 was
not [40]. This N-glycosylation was shown to be critical for the regulation of ligand (S100B)
binding with potential consequences for NFКB pathway activation in HEK293 cells expressing
RAGE [40]. In our epithelial cell system the RAGE-Ser82 variant was significantly associated
with decreased levels of secretion of sRAGE by the cell in response to activation with the
ligand HMGB1. One limitation of the cell experiments is that we did not also measure NFКB
pathway activation which would have provided greater depth to our findings. However, taken
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together, these data suggest that rs2070600 is likely to be the functional variant which
accounts for the observed association with lung function variables as our in vitromodel only
contains this specific variant change, as opposed to other SNPs in linkage disequilibrium (LD)
with rs2070600 [5].
It has been robustly demonstrated that sRAGE levels in serumor plasma of COPD patients
is lower compared to control subjects and associated with GOLD stage and markers of emphy-
sema (reviewed by Yonchuk et al 2015)[41]. This led to the concept that this lower level of
sRAGE, which acts as a decoy receptor to limit inflammationmay lead to greater RAGE driven
inflammation in COPD. A limitation of our study is that by using samples from a general pop-
ulation of smokers with and without COPD we did not have data on the extent of emphysema
in the individuals with COPD. Additional studies investigating the distribution of RAGE/
sRAGE within the lung would help (i) clarify the source(s) of serum sRAGE (potentially alveo-
lar epithelial cells or pulmonary capillary endothelial cells) and (ii) identify if the relative con-
tribution of these sources is altered in COPD.
The relationship betweenAGER genetics, lung function and sRAGE levels is potentially
counterintuitive as the rs2070600T allele is associated with better lung function in the general
population and lower sRAGE. The molecularmechanisms underlying these observations still
remain to be defined, however our novel data provide supporting evidence that rs2070600 is
the key SNP driving sRAGE levels in the cell assays. The key SNP(s) driving the association
with lung function and COPD diagnosis at the population level remain to be elucidated and
similarly whether rs2070600 contributes to lung function and sRAGE via overlapping or dis-
tinct mechanisms is an important, unresolved question.
In summary, we provide important new information regarding the expression profile of
RAGE in the human lung by identifying the isoforms present, and by assessing differential
expression in human fetal lung development and in human airways from control individuals
and those with COPD. The T allele of rs2070600, which codes for the RAGE-Ser82 variant, was
found to be associated with increased lung function in a cohort of UK smokers and the levels of
sRAGE were found to be lower in the serumof smoking individuals carrying this variant.
These data provide novel insight into the role of AGER/RAGE in lung biology and support a
functional role for rs2070600 in determining sRAGE levels, which may in turn explain the
association seen between this variant and function.
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